Cas:110105-35-6 N-(4-Pyridinyl)-4-piperidinecarboxamide manufacturer & supplier

We serve Chemical Name:N-(4-Pyridinyl)-4-piperidinecarboxamide CAS:110105-35-6 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

N-(4-Pyridinyl)-4-piperidinecarboxamide

Chemical Name:N-(4-Pyridinyl)-4-piperidinecarboxamide
CAS.NO:110105-35-6
Synonyms:N-(pyridin-4-yl)piperidine-4-carboxamide;N-(4-Pyridinyl)-4-piperidinecarboxamide;4-Piperidinecarboxamide, N-4-pyridinyl-;4-Piperidinecarboxamide,N-4-pyridinyl
Molecular Formula:C11H15N3O
Molecular Weight:205.256
HS Code:

Physical and Chemical Properties:
Melting point:N/A
Boiling point:439.9±35.0 °C at 760 mmHg
Density:1.2±0.1 g/cm3
Index of Refraction:1.583
PSA:54.02000
Exact Mass:205.121506
LogP:0.79

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like N-(pyridin-4-yl)piperidine-4-carboxamide chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,4-Piperidinecarboxamide,N-4-pyridinyl physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,N-(pyridin-4-yl)piperidine-4-carboxamide Use and application,N-(4-Pyridinyl)-4-piperidinecarboxamide technical grade,usp/ep/jp grade.


Related News: Plexxikon filed a lawsuit against the pharma giant in 2017, alledging that Tafinlar, a rival to its melanoma drug Zelboraf that was brought to market in collaboration with Roche, has stepped on its intellectual property. The jury ruled in its favor, adding that the infringement is in fact willful. Methyl 6-methyl-1H-indazole-3-carboxylate manufacturers He further explained that getting a new drug to commercial manufacturing is also complex and costly due to the very stringent drug manufacturing regulatory mechanism. 2-Fluoro-4-(4-methyl-1-piperazinyl)benzaldehyde suppliers “This announcement reflects another important regulatory milestone in the development of this medicine,” said Roy Baynes, senior vice president and head of global clinical development, chief medical officer, Merck Research Laboratories. 2,3-dibroMo-6,7-dichloroquinoxaline vendor & factory.